Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves treatment for patients with a type of inflammatory arthritis


SILVER SPRING, Md., March 28, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"Today's approval of Cimzia fulfills an unmet need for patients suffering from non-radiographic axial spondyloarthritis as there has been no FDA-approved treatments until now," said Nikolay Nikolov, M.D., associate director for rheumatology of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA's Center for Drug Evaluation and Research.

Nr-axSpA is a type of inflammatory arthritis that causes inflammation in the spine and other symptoms. There is no visible damage seen on x-rays, so it is referred to as non-radiographic.

The efficacy of Cimzia for the treatment of nr-axSpA was studied in a randomized clinical trial in 317 adult patients with nr-axSpA with objective signs of inflammation, indicated by elevated C-reactive protein (CRP) levels and/or sacroiliitis (inflammation of the sacroiliac joints) on MRI. The trial measured the improvement response on the Ankylosing Spondylitis Disease Activity Score, a composite scoring system that assesses disease activity including patient-reported outcomes and CRP levels. Responses were greater for patients treated with Cimzia compared to patients treated with placebo. The overall safety profile observed in the Cimzia treatment group was consistent with the known safety profile of Cimzia.

The prescribing information for Cimzia includes a Boxed Warning to advise health care professionals and patients about the increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis (infection in the blood steam), invasive fungal infections (such as histoplasmosis, an infection that affects the lungs), and other infections. Cimzia should be discontinued if a patient develops a serious infection or sepsis. Health care providers are advised to perform testing for latent TB and, if positive, to start treatment for TB prior to starting Cimzia. All patients should be monitored for active TB during treatment, even if the initial latent TB test is negative. The Boxed Warning also advises that lymphoma (cancer in blood cells) and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, of which Cimzia is a member. Cimzia is not indicated for use in pediatric patients. Cimzia must be dispensed with a patient Medication Guide that describes important information about the drug's uses and risks.

Cimzia was originally approved in 2008 and is also indicated for adult patients with Crohn's disease, moderate-to-severe rheumatoid arthritis, active ankylosing spondylitis (AS) and moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The FDA granted the approval of Cimzia to UCB.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Nathan Arnold, 301-796-6248, nathan.arnold@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 13:08
Update This notice has been updated to reflect a new outbreak of Salmonella illnesses linked to frozen raw breaded chicken products, and a new food recall warning that is related to illnesses reported in this active outbreak investigation. Why you...

at 11:55
Heritage Pharmaceuticals Inc. ("Heritage") East Brunswick, New Jersey, is initiating a voluntary recall of Amikacin Sulfate Injection, USP, 1g/4 mL (250mg/mL), Lot: VEAC025, Expiry Date: October 2019 and Prochlorperazine Edisylate Injection, USP,...

at 10:00
The 3-day power-packed event, October 3rd ? 5th, has a line up of 27 speakers, including New York Times bestselling author Harry S. Dent. He studied economics before publishing 14 books about economic planning and forecasting. He also earned an MBA...

at 10:00
An April 23 article on Salon detailed yet another health fad that may not be as promising as its marketing suggests: kombucha, a popular tea-based fermented drink. The drink is said to aid in a variety of health-related areas including digestion,...

at 03:00
The Spine Institute is more than just a clinic. It's a place where patients receive the most innovative and advanced treatments. Founded by the highly regarded surgeon and NJ Top Doc, Dr. Marc A. Cohen, the Spine Institute treats adults suffering...

at 03:00
There is one crucial detail that sports analysts are likely to miss when dissecting the masterful performances of Wayne Gretzky, Serena Williams, Muhammad Ali, Usain Bolt, or Bruce Lee: The secret to their success wasn't muscle deep. Granted, their...



News published on 28 march 2019 at 14:33 and distributed by: